Cervical cancer in the COVID-19 era – the potential role of adapting newer treatment protocols

Bindhu Joseph, Nikhila Radhakrishna, Nithin Bhaskar Valuvil, Lokesh Vishwanath


Background: The COVID-19 pandemic has resulted in unprecedented problems in cancer management and providing a safe organised work flow for oncological health care systems to operate.

The treatment of advanced cervical cancer stage IIB - IVA has received higher priority in most international guidelines for risk adaptation in relation to COVID-19 situation.

There is an urgent need to revise the established standard treatment protocol of concurrent chemo-irradiation followed by brachytherapy, usually delivered over 6-7 weeks, which is associated with technical difficulties and would pose risks to both the patient and treating health care personnel.

Aims & Objectives: To propose alternative treatment protocols that are supported by scientific data and may be better suited to meet the needs of the unique situation.

Methods: A systematic literature search was performed using PubMed and other search engines. The studies evaluated were those published from 1990 to April 2020. The focus was on scientific rationale and non-inferiority with standards of care.

Conclusions: The authors propose Simultaneous Integrated Boost for treatment of large volume disease and Stereotactic Body Radiotherapy boost for smaller tumour volumes, where facilities are available. 3DCRT with an integrated or sequential IMRT boost can be considered in institutes with technical limitations.


Cervical cancer ; SBRT ; SIB ; EBRT Boost

Full Text:



Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-733

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648

Bogoch II, Watts A, Thomas-Bachli A, et al. Potential for global spread of a novel coronavirus from China. J Travel Med. 2020. [PMID: 31985790] doi:10.1093/jtm/taaa011

Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer – NHS 2020

Arbyn M., Weiderpass E., Bruni L., de Sanjose S., Saraiya M., Ferlay J., Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis The Lancet Global Health 2019, 8 (2) , pp. e191-e203. PMID31812369. DOI10.1016/s2214-109x(19)30482-6

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492

Chopra SJ, Mathew A, Maheshwari A, Bhatla N, Singh S, Rai B et al. National Cancer Grid of India Consensus Guidelines on the Management of Cervical Cancer. Journal of Global Oncology 2018 :4, 1-15

van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, Kok HP. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018 May 16;13(1):96. doi: 10.1186/s13014-018-1040-z. PMID: 29769103; PMCID: PMC5956964.

Lanciano RM, Won M, Coia LR, Hanks GE. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys 1991;20:667-76

Montana GS, Hanlon AL, Brickner TJ, Owen JB, Hanks GE, Ling CC, et al. Carcinoma of the cervix: Patterns of care studies: Review of 1978, 1983, and 1988-1989 surveys. Int J Radiat Oncol Biol Phys 1995;32:1481-6

Robin TP, Amini A,Schefter TE, et al. Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer. Gynecol Oncol. 2016;143:319–325.

Matsuura K, Okabe T, Fujita K, Tanimoto H, Akagi Y, Kagemoto M. Clinical results of external beam radiotherapy alone with a concomitant boost program or with conventional fractionation for cervical cancer patients who did not receive intracavitary brachytherapy. J Radiat Res. 2012 Nov 1;53(6):900-5. doi: 10.1093/jrr/rrs051. Epub 2012 Aug 1. PMID: 22859563; PMCID: PMC3483852.

Lazzari R, Riva G, Augugliaro M, et al. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy. International Journal of Gynecologic Cancer Published Online First: 17 March 2020. doi: 10.1136/ijgc-2019-000735

Mahmoud O, Kilic S, Khan AJ, Beriwal S, Small W Jr. External beam techniques to boost cervical cancer when brachytherapy is not an option-theories and applications. Ann Transl Med. 2017 May;5(10):207. doi: 10.21037/atm.2017.03.102. PMID: 28603722; PMCID: PMC5451624.

Chuang LT, Temin S, Berek JS. Management and Care of Women With Invasive Cervical Cancer: American Societyof Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract 2016;12:693-6

Mazzola R, Ricchetti F, Fiorentino A, et al. Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results. Technol Cancer Res Treat 2017;16:310-5.

Guerrero M, Li XA, Ma L, Linder J, Deyoung C, Erickson B. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations. Int J Radiat Oncol Biol Phys. 2005;62(3):933–939. doi:10.1016/j.ijrobp.2004.11.040

Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94.

Buffa FM, Davidson SE, Hunter RD, et al. Incorporating biologic measurements (SF(2), CFE) into a tumor control probability model increases their prognostic significance: a study in cervical carcinoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:1113-22.

Gasinska A, Fowler JF, Lind BK, et al. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone. Acta oncologica 2004;43:657-66.

Vandecasteele K, Makar A, Van den Broecke R, et al. Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome. Strahlenther Onkol. 2012;188(7):576-581.

Wang X, Zhao Y, Shen Y, et al. Long-term follow-up results of simultaneous integrated or late course accelerated boost with external beam radiotherapy to vaginal cuff for high risk cervical cancer patients after radical hysterectomy. BMC Cancer. 2015;15:257.

Khosla D, Patel FD, Rai B, et al. Dose esca¬lation by intensity-modulated radiotherapy boost after whole pelvic radiotherapy in postoperative patients of carcinoma cervix with residual disease. Clin Oncol (R Coll Radiol). 2013;25(1):e1-6.

Marnitz S, Kohler C, Budach V, et al. Brachytherapy-emulating robotic radiosurgery in patients with cervical carcinoma. Radiation oncology 2013;8:109.

Haas JA, Witten MR, Clancey O, et al. CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy. Front Oncol 2012;2:25.

Kubicek GJ, Xue J, Xu Q, et al. Stereotactic body radiotherapy as an alternative to brachytherapy in gynecologic cancer. Biomed Res Int 2013;2013:898953

Mantz C. Stereotactic Body Radiation Therapy as a Boost Alternative for Nonmetastatic Cancer of the Cervix and Endometrium: Disease Control and Quality of Life Outcomes From a Phase 2 Trial at 3 Years’ Minimum Follow-up. Int J Radiat Oncol Biol Phys 2016;96:E286.

Cengiz M, Dogan A, Ozyigit G, et al. Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer. Brachytherapy 2012;11:125-9.

Hsieh CH, Tien HJ, Hsiao SM, et al. Stereotactic body radiation therapy via helical tomotherapy to replace brachytherapy for brachytherapy-unsuitable cervical cancer patients - a preliminary result. Onco Targets Ther 2013;6:59-66.

Clivio A, Kluge A, Cozzi L, et al. Intensity modulated proton beam radiation for brachytherapy in patients with cervical carcinoma. Int J Radiat Oncol Biol Phys. 2013;87(5):897–903. doi:10.1016/j.ijrobp.2013.08.027

Chan P, Yeo I, Perkins G, et al. Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study. Radiat Oncol 2006;1:13.

Barraclough LH, Swindell R, Livsey JE, et al. External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed. Int J Radiat Oncol Biol Phys 2008;71:772-8.

Molla M, Escude L, Nouet P, et al. Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? Int J Radiat Oncol Biol Phys. 2005; 62(1):118-24.

Jorcano S, Molla M, Escude L, et al. Hypofractionated extracranial stereotactic radiotherapy boost for gynecologic tumors: a promising alternative to high-dose rate brachytherapy. Technol Cancer Res Treat. 2010;9(5):509-514.

Park HC, Shimizu S, Yonesaka A, et al. High dose three-dimensional conformal boost using the real-time tumor tracking radiotherapy system in cervical cancer patients unable to receive intracavitary brachytherapy. Yonsei Med J.2010;51(1):93-99.

DOI: http://dx.doi.org/10.30564/amor.v6i1.209


  • There are currently no refbacks.

Copyright (c) 2020 Bindhu Joseph, Nikhila Radhakrishna, Nithin Bhaskar Valuvil, Lokesh Vishwanath

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.